{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000057","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-07-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.831773+00:00","generated_at":"2026-06-24T16:01:37.601643+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share","bullets":["Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.","Participation by EcoR1 Capital, NEA, Weiss Asset Management, Rock Springs Capital, and others.","Proceeds to fund seralutinib R&D ahead of Phase 2 TORREY topline results in Q4 2022.","Expected close July 15, 2022; lock-up on shares until October 1, 2022.","Cash runway extended into mid-2024 with existing cash and debt facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000057","json":"https://secwatch.observer/filing/0001728117-22-000057.json","markdown":"https://secwatch.observer/filing/0001728117-22-000057.md","text":"https://secwatch.observer/filing/0001728117-22-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000057/0001728117-22-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000057/goss-20220713.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T16:01:37.601643+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}